Elite in Colitis

Dan L. Turner

Singleton Park, 
Swansea, WLS, GB 
Elite in Colitis
Singleton Park, 
Swansea, WLS, GB 
OverviewLocationsClinical Research

Overview

Dan Turner practices in Swansea, United Kingdom. Mr. Turner is rated as an Elite expert by MediFind in the treatment of Colitis. His top areas of expertise are Viral Gastroenteritis, Colitis, Hemorrhagic Proctocolitis, Colonoscopy, and Endoscopy.

His clinical research consists of co-authoring 322 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 112 articles and participated in 4 clinical trials in the study of Colitis.

Gender
Male

Locations

Singleton Park, Swansea, WLS, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Darvadstrocel in the Treatment of Complex Perianal Fistula in Pediatric Subjects With Crohn's Disease Over a Period of 24 Weeks and an Extended Follow-up Period for a Total of up to 52 Weeks
A Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Darvadstrocel in the Treatment of Complex Perianal Fistula in Pediatric Subjects With Crohn's Disease Over a Period of 24 Weeks and an Extended Follow-up Period for a Total of up to 52 Weeks
Enrollment Status: Terminated
Publish Date: November 13, 2025
Intervention Type: Biological
Study Drug: Darvadstrocel
Study Phase: Phase 3
A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous as Maintenance Therapy in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous as Maintenance Therapy in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
Enrollment Status: Completed
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drug: Vedolizumab
Study Phase: Phase 3
Preventing IBD Onset in Individuals at Risk
Preventing IBD Onset in Individuals at Risk
Enrollment Status: Active_not_recruiting
Publish Date: August 21, 2025
Intervention Type: Other
Study Phase: Not Applicable
Tasty&Healthy is Not a Diet But a Dietary Approach: Randomized Controlled Trials of Excluding Pro-inflammatory Nutrients for Inducing and Maintaining Remission in Crohn's Disease
Tasty&Healthy is Not a Diet But a Dietary Approach: Randomized Controlled Trials of Excluding Pro-inflammatory Nutrients for Inducing and Maintaining Remission in Crohn's Disease
Enrollment Status: Completed
Publish Date: April 27, 2025
Intervention Type: Dietary supplement
Study Phase: Not Applicable
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
A Multicenter, Open-Label PK Study of Mirikizumab in Pediatric Patients With Moderately to Severely Active Ulcerative Colitis
A Multicenter, Open-Label PK Study of Mirikizumab in Pediatric Patients With Moderately to Severely Active Ulcerative Colitis
Enrollment Status: Completed
Publish Date: March 26, 2024
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 2
Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases (IBD) Including Drug Levels: a Multi-center Prospective Cohort Study, From the Pediatric IBD Porto Group of European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN)
Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases (IBD) Including Drug Levels: a Multi-center Prospective Cohort Study, From the Pediatric IBD Porto Group of European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN)
Enrollment Status: Completed
Publish Date: October 25, 2022
Intervention Type: Drug
Study Drug: Vedolizumab
Study Phase: Not Applicable
Manipulating the Microbiome in IBD by Antibiotics and Fecal Microbiota Transplantation (FMT): a Randomized Controlled Trial
Manipulating the Microbiome in IBD by Antibiotics and Fecal Microbiota Transplantation (FMT): a Randomized Controlled Trial
Enrollment Status: Completed
Publish Date: October 08, 2021
Intervention Type: Drug
Study Drugs: Vancomycin, Amoxycillin, Doxycyline, Ciprofloxacin, Methylprednisolone, Metronidazole
Study Phase: Not Applicable
The ImageKids Study: Developing the Pediatric MR Enterography-based Damage Index in Crohn's Disease (pMEDIC) and the Pediatric Inflammatory Crohn's MRE Index (PICMI)
The ImageKids Study: Developing the Pediatric MR Enterography-based Damage Index in Crohn's Disease (pMEDIC) and the Pediatric Inflammatory Crohn's MRE Index (PICMI)
Enrollment Status: Completed
Publish Date: May 01, 2017
Intervention Type: Device
Study Phase: Not Applicable
View 8 Less Clinical Trials

322 Total Publications

Validation of prediction models for anti-tumor necrosis factor treatment response in pediatric Crohn's disease: a systematic review and prospective cohort study.
Validation of prediction models for anti-tumor necrosis factor treatment response in pediatric Crohn's disease: a systematic review and prospective cohort study.
Journal: Journal of Crohn's & colitis
Published: September 19, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Turner's expertise for a condition
ConditionClose
View All 16 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile